Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study)

Nicola Gianotti, Laura Galli, Renato Maserati, Laura Sighinolfi, Diego Ripamonti, Loredana Palvarini, Sergio Lo Caputo, Emanuele Focà, Benedetto Maurizio Celesia, Franco Baldelli, Gaetana Sterrantino, Adriano Lazzarin

Research output: Contribution to journalArticle

Abstract

In a multicentre, open-label, clinical trial, 43 patients virologically suppressed while receiving a standard triple antiretroviral therapy were randomized (1:1:1) to switch to monotherapy with darunavir/ritonavir (DRV/r-MT arm), monotherapy with lopinavir/ritonavir (LPV/r-MT arm) or to continue on the ongoing regimen (cART arm). The proportion (95% CI) of patients with virological success (Snapshot analysis) at week 48 was 73% (48%-90%) in the DRV/r-MT arm, 69% (42%-88%) in the LPV/r-MT arm and 87% (61%-98%) in the cART arm. Virological failure was detected in only one patient receiving LPV/r-MT. The LPV/r-MT arm showed a modest worsening in lipid profile.

Original languageEnglish
Pages (from-to)290-294
Number of pages5
JournalNew Microbiologica
Volume39
Issue number4
Publication statusPublished - Oct 2016

Fingerprint

Lopinavir
Ritonavir
Randomized Controlled Trials
Therapeutics
Clinical Trials
Lipids
Darunavir

Keywords

  • Journal Article

Cite this

Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy : a randomized clinical trial (2pm Study). / Gianotti, Nicola; Galli, Laura; Maserati, Renato; Sighinolfi, Laura; Ripamonti, Diego; Palvarini, Loredana; Caputo, Sergio Lo; Focà, Emanuele; Celesia, Benedetto Maurizio; Baldelli, Franco; Sterrantino, Gaetana; Lazzarin, Adriano.

In: New Microbiologica, Vol. 39, No. 4, 10.2016, p. 290-294.

Research output: Contribution to journalArticle

Gianotti, N, Galli, L, Maserati, R, Sighinolfi, L, Ripamonti, D, Palvarini, L, Caputo, SL, Focà, E, Celesia, BM, Baldelli, F, Sterrantino, G & Lazzarin, A 2016, 'Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study)', New Microbiologica, vol. 39, no. 4, pp. 290-294.
Gianotti, Nicola ; Galli, Laura ; Maserati, Renato ; Sighinolfi, Laura ; Ripamonti, Diego ; Palvarini, Loredana ; Caputo, Sergio Lo ; Focà, Emanuele ; Celesia, Benedetto Maurizio ; Baldelli, Franco ; Sterrantino, Gaetana ; Lazzarin, Adriano. / Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy : a randomized clinical trial (2pm Study). In: New Microbiologica. 2016 ; Vol. 39, No. 4. pp. 290-294.
@article{9ce4bf3609f241818e020ef21aa3d1d1,
title = "Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study)",
abstract = "In a multicentre, open-label, clinical trial, 43 patients virologically suppressed while receiving a standard triple antiretroviral therapy were randomized (1:1:1) to switch to monotherapy with darunavir/ritonavir (DRV/r-MT arm), monotherapy with lopinavir/ritonavir (LPV/r-MT arm) or to continue on the ongoing regimen (cART arm). The proportion (95{\%} CI) of patients with virological success (Snapshot analysis) at week 48 was 73{\%} (48{\%}-90{\%}) in the DRV/r-MT arm, 69{\%} (42{\%}-88{\%}) in the LPV/r-MT arm and 87{\%} (61{\%}-98{\%}) in the cART arm. Virological failure was detected in only one patient receiving LPV/r-MT. The LPV/r-MT arm showed a modest worsening in lipid profile.",
keywords = "Journal Article",
author = "Nicola Gianotti and Laura Galli and Renato Maserati and Laura Sighinolfi and Diego Ripamonti and Loredana Palvarini and Caputo, {Sergio Lo} and Emanuele Foc{\`a} and Celesia, {Benedetto Maurizio} and Franco Baldelli and Gaetana Sterrantino and Adriano Lazzarin",
year = "2016",
month = "10",
language = "English",
volume = "39",
pages = "290--294",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "4",

}

TY - JOUR

T1 - Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy

T2 - a randomized clinical trial (2pm Study)

AU - Gianotti, Nicola

AU - Galli, Laura

AU - Maserati, Renato

AU - Sighinolfi, Laura

AU - Ripamonti, Diego

AU - Palvarini, Loredana

AU - Caputo, Sergio Lo

AU - Focà, Emanuele

AU - Celesia, Benedetto Maurizio

AU - Baldelli, Franco

AU - Sterrantino, Gaetana

AU - Lazzarin, Adriano

PY - 2016/10

Y1 - 2016/10

N2 - In a multicentre, open-label, clinical trial, 43 patients virologically suppressed while receiving a standard triple antiretroviral therapy were randomized (1:1:1) to switch to monotherapy with darunavir/ritonavir (DRV/r-MT arm), monotherapy with lopinavir/ritonavir (LPV/r-MT arm) or to continue on the ongoing regimen (cART arm). The proportion (95% CI) of patients with virological success (Snapshot analysis) at week 48 was 73% (48%-90%) in the DRV/r-MT arm, 69% (42%-88%) in the LPV/r-MT arm and 87% (61%-98%) in the cART arm. Virological failure was detected in only one patient receiving LPV/r-MT. The LPV/r-MT arm showed a modest worsening in lipid profile.

AB - In a multicentre, open-label, clinical trial, 43 patients virologically suppressed while receiving a standard triple antiretroviral therapy were randomized (1:1:1) to switch to monotherapy with darunavir/ritonavir (DRV/r-MT arm), monotherapy with lopinavir/ritonavir (LPV/r-MT arm) or to continue on the ongoing regimen (cART arm). The proportion (95% CI) of patients with virological success (Snapshot analysis) at week 48 was 73% (48%-90%) in the DRV/r-MT arm, 69% (42%-88%) in the LPV/r-MT arm and 87% (61%-98%) in the cART arm. Virological failure was detected in only one patient receiving LPV/r-MT. The LPV/r-MT arm showed a modest worsening in lipid profile.

KW - Journal Article

M3 - Article

C2 - 27551725

VL - 39

SP - 290

EP - 294

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 4

ER -